Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

Company Overview

Olema Pharmaceuticals is a clinical‐stage biopharmaceutical company headquartered in Redwood City, California, focused on developing novel small‐molecule therapies for the treatment of hormone receptor–positive (HR+) breast cancer and other estrogen‐driven malignancies. The company’s pipeline leverages a proprietary platform for designing oral selective estrogen receptor degraders (SERDs) that aim to overcome resistance mechanisms associated with existing endocrine therapies. Olema’s research and development facilities are complemented by strategic collaborations with academic institutions and contract research organizations across North America and Europe.

At the center of Olema’s development efforts is its lead candidate, OLP‐108, an orally bioavailable SERD engineered to bind and degrade the estrogen receptor with improved pharmacokinetic properties relative to first‐generation agents. Preclinical studies have demonstrated potent antitumor activity in models of both treatment‐naïve and endocrine‐resistant HR+ breast cancer. In addition, Olema is advancing a preclinical portfolio of next‐generation endocrine modulators that exploit complementary mechanisms of action, including selective estrogen receptor modulators (SERMs) and combination regimens with CDK4/6 inhibitors.

Since its founding in 2019, Olema Pharmaceuticals has grown from a small discovery team to a fully integrated development organization with discovery, translational biology and clinical operations capabilities. The company’s management has filed multiple investigational new drug (IND) applications and initiated Phase 1 and Phase 2 clinical trials in the United States. Olema also maintains a presence in Europe to support multinational studies and regulatory interactions with the European Medicines Agency (EMA).

Under the leadership of Chief Executive Officer Lindsey Rolfe, a biotech veteran with over 20 years of experience in oncology drug development, Olema continues to expand its scientific advisory board and executive team. The company’s leadership includes experts in medicinal chemistry, pharmacology and clinical oncology, all working toward the common goal of delivering new oral therapies that address unmet needs in breast cancer treatment and beyond.

Key Stats

• Today's Range: $4.60 to $4.85
• 50-Day Range: $4.01 to $5.56
• 52-Week Range: $2.86 to $16.62
• Volume: 300,510 shs
• Average Volume: 819,524 shs
• Market Capitalization: $318.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.50
• Consensus Rating: Buy

Olema Pharmaceuticals Stock Analysis - MarketRank™

Olema Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 592nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Olema Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Olema Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.33) to ($2.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Olema Pharmaceuticals is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Olema Pharmaceuticals is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Olema Pharmaceuticals has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.24% of the float of Olema Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Olema Pharmaceuticals has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Olema Pharmaceuticals has recently increased by 21.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Olema Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Olema Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.24% of the float of Olema Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Olema Pharmaceuticals has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Olema Pharmaceuticals has recently increased by 21.64%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Olema Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Olema Pharmaceuticals this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Olema Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.36% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OLMA Stock Analysis - Frequently Asked Questions

How have OLMA shares performed this year?

Olema Pharmaceuticals' stock was trading at $5.83 at the start of the year. Since then, OLMA stock has decreased by 20.2% and is now trading at $4.65.

How were Olema Pharmaceuticals' earnings last quarter?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) posted its earnings results on Tuesday, May, 13th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13.

When did Olema Pharmaceuticals IPO?

Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering on Thursday, November 19th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity acted as the underwriters for the IPO.

Who are Olema Pharmaceuticals' major shareholders?

Olema Pharmaceuticals' top institutional shareholders include Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Bain Capital Life Sciences Inv, Bvf Partners L P/Il, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen and Naseem Zojwalla.
View institutional ownership trends.

How do I buy shares of Olema Pharmaceuticals?

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Olema Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Olema Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OLMA
• CIK: 1750284
• Web: www.olema.com
• Phone: 650-243-5555
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Olema Pharmaceuticals: $24.50
• High Price Target: $30.00
• Low Price Target: $18.00
• Potential Upside/Downside: +426.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$129.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -42.31%
• Return on Assets: -38.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.22
• Quick Ratio: 15.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.14 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 68,420,000
• Free Float: 57,227,000
• Market Cap: $318.15 million
• Optionable: Optionable
• Beta: 1.90